296 related articles for article (PubMed ID: 23847759)
1. Immunotherapy for pediatric leukemia.
Shah NN; Dave H; Wayne AS
Front Oncol; 2013; 3():166. PubMed ID: 23847759
[TBL] [Abstract][Full Text] [Related]
2. Application of immunotherapy in pediatric leukemia.
Wayne AS
Curr Hematol Malig Rep; 2009 Jul; 4(3):159-66. PubMed ID: 20425429
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in Acute Leukemias: Past Success Paves the Way for Future Progress.
Chergui A; Reagan JL
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627165
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in pediatric B-cell acute lymphoblastic leukemia.
Wyatt KD; Bram RJ
Hum Immunol; 2019 Jun; 80(6):400-408. PubMed ID: 30716352
[TBL] [Abstract][Full Text] [Related]
5. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation.
Bertaina A; Roncarolo MG
Front Immunol; 2019; 10():1342. PubMed ID: 31354695
[TBL] [Abstract][Full Text] [Related]
6. Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy--from bench to patient bedside.
Slavin S; Morecki S; Weiss L; Shapira MY; Resnick I; Or R
Semin Oncol; 2004 Feb; 31(1):4-21. PubMed ID: 14970932
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives.
Lv M; Liu Y; Liu W; Xing Y; Zhang S
Front Immunol; 2022; 13():921894. PubMed ID: 35769486
[TBL] [Abstract][Full Text] [Related]
8. Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach.
Sinkovics JG
Acta Microbiol Immunol Hung; 2010 Dec; 57(4):253-347. PubMed ID: 21183421
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of childhood cancer: from biologic understanding to clinical application.
Wayne AS; Capitini CM; Mackall CL
Curr Opin Pediatr; 2010 Feb; 22(1):2-11. PubMed ID: 19952749
[TBL] [Abstract][Full Text] [Related]
10. Adoptive transfer of T cells transduced with a chimeric antigen receptor to treat relapsed or refractory acute leukemia: efficacy and feasibility of immunotherapy approaches.
Ding G; Chen H
Sci China Life Sci; 2016 Jul; 59(7):673-7. PubMed ID: 27142351
[TBL] [Abstract][Full Text] [Related]
11. The future of cellular immunotherapy for childhood leukemia.
Bonifant CL; Tasian SK
Curr Opin Pediatr; 2020 Feb; 32(1):13-25. PubMed ID: 31851053
[TBL] [Abstract][Full Text] [Related]
12. Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia.
Llaurador G; Shaver K; Wu M; Wang T; Gillispie A; Doherty E; Craddock J; Read J; Yassine K; Morales E; George A; Steffin D; Krance R; Martinez C; Heslop H; Salem B
Transplant Cell Ther; 2024 Feb; 30(2):217-227. PubMed ID: 37931800
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: current status and future directions mainly focusing on a Chinese perspective.
Ma R; Liu XT; Chang YJ
Expert Rev Hematol; 2022 Sep; 15(9):789-803. PubMed ID: 36106497
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial.
Buhmann R; Michael S; Juergen H; Horst L; Peschel C; Kolb HJ
J Transl Med; 2013 Jul; 11():160. PubMed ID: 23815981
[TBL] [Abstract][Full Text] [Related]
15. Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.
Griggio V; Perutelli F; Salvetti C; Boccellato E; Boccadoro M; Vitale C; Coscia M
Front Immunol; 2020; 11():594556. PubMed ID: 33312177
[TBL] [Abstract][Full Text] [Related]
16. Relapsed/Refractory T- Acute Lymphoblastic Leukemia - Current Options and Future Directions.
Jeha S
Indian J Pediatr; 2024 Feb; 91(2):168-175. PubMed ID: 37642889
[TBL] [Abstract][Full Text] [Related]
17. Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients.
Asare JM; Rabik CA; Muller B; Brown PA; Cooper S
Expert Opin Investig Drugs; 2021 Jun; 30(6):611-620. PubMed ID: 33896328
[No Abstract] [Full Text] [Related]
18. Immunotherapy in hematologic malignancies: achievements, challenges and future prospects.
Tang L; Huang Z; Mei H; Hu Y
Signal Transduct Target Ther; 2023 Aug; 8(1):306. PubMed ID: 37591844
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the management of pediatric acute lymphoblastic leukemia.
Starý J; Hrušák O
F1000Res; 2016; 5():2635. PubMed ID: 29098074
[TBL] [Abstract][Full Text] [Related]
20. Advances in immunotherapy for pediatric acute myeloid leukemia.
Bonifant CL; Velasquez MP; Gottschalk S
Expert Opin Biol Ther; 2018 Jan; 18(1):51-63. PubMed ID: 28945115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]